JP4564076B2 - Porous spherical metasilicate colloidal solution - Google Patents

Description

  The present invention relates to a metasilicate solution containing a water-soluble metasilicate, a food and drink containing the metasilicate solution, and an agent for preventing or improving renal dysfunction and diabetes.

Silicates are widely distributed in the soil and other environments, and animals such as humans ingest very small amounts of silicate on a daily basis, and humans are affected by silicates in some way. it is conceivable that. However, the use of silicates is limited to industrial uses such as silicon wafer materials, and we examined in detail the effects of silicates (SiO ₃ ²⁻ ) on the living body and the presence or absence of health damage due to overdose. There is little research.

Korean Patent No. 10-058952 (Patent Document 1) describes a method in which quartz is baked at a high temperature and taken out as a water-soluble metasilicate. Although the metasilicate obtained by this method has high water solubility, no effect on renal function or diabetes has been reported, and inconveniences such as stomach upset when ingested in large amounts by humans.
Korean Patent No. 10-058952

  Accordingly, an object of the present invention is to provide a silicate solution that works well on the biological functions of animals including humans.

  As a result of diligent research in view of the above-mentioned purpose, the present inventors can improve the pathology of renal dysfunction or diabetes by using metasilicate as an alkaline solution, and improve the stability of an aqueous solution, and when ingested As a result of further research, the present invention has been completed.

  That is, the present invention relates to a metasilicate solution containing a water-soluble metasilicate and water and having a pH of 8 to 12.

Moreover, this invention relates to the said metasilicate solution obtained from the composite aqueous solution containing the metasilicate derived from a silicon oxide mineral, calcium or a calcium salt, and magnesium.
Furthermore, this invention relates to the said metasilicate solution containing 10-1000 mg / L of metasilicate as silicon.
Moreover, this invention relates to the said metasilicate solution containing 500-1000 mg / L of metasilicate as silicon.
Furthermore, this invention relates to the said metasilicate solution containing 10-100 mg / L of metasilicate as a silicon.
Moreover, this invention relates to the said metasilicate solution whose pH is 10-12.
Furthermore, this invention relates to the said metasilicate solution whose pH is 8-9.

Moreover, this invention relates to the food / beverage containing the said metasilicate solution.
Furthermore, this invention relates to the said food-drinks which are mineral water.

The present invention also relates to a preventive or ameliorating agent for renal dysfunction containing the metasilicate solution.
Furthermore, this invention relates to the preventive agent or ameliorating agent of diabetes containing the said metasilicate solution.

  According to the present invention, renal dysfunction or diabetes can be improved by taking water-soluble metasilicate as a food or drink or oral preparation. Water-soluble metasilicates can also be used to prevent renal dysfunction or diabetes. Furthermore, by using an alkaline solution containing a water-soluble metasilicate, it is possible to prevent undesirable effects such as stomach sag and stabilize the aqueous solution. In particular, the stability can be further improved by using a metasilicate solution as a concentrate.

[I] Metasilicate Solution The metasilicate solution of the present invention contains a water-soluble metasilicate. The water-soluble metasilicate is not particularly limited as long as it is highly soluble in water, but is preferably a metasilicate derived from a silicon oxide mineral (quartz, quartz, etc.), particularly preferably a Korean patent. It is a metasilicate obtained by baking a crystal at 1650 ° C. or higher and recovering it after it is gasified as described in No. 10-058952 (product name: Siripoli, SILIPOLY, manufactured by Korea Escam).

  The form of the salt of metasilicate is not particularly limited, and alkali metal salts such as sodium metasilicate and potassium metasilicate, alkaline earth metal salts such as calcium metasilicate and magnesium metasilicate, calcium dialumanometasilicate and the like are used. Can do.

  The metasilicate in the metasilicate solution of the present invention can be used in the range of 10 to 1000 mg / L as silicon. For example, when the metasilicate solution is used as it is as a food or drink (for example, mineral water), or as a preventive or ameliorating agent for renal dysfunction or as a prophylactic or ameliorating agent for diabetes, the concentration of metasilicate in the metasilicate solution is silicon. Preferably it is 10-100 mg / L, More preferably, it is 20-50 mg / L. Moreover, when using as a concentrate which dilutes a metasilicate solution at the time of use, the density | concentration of the metasilicate in a metasilicate solution becomes like this. Preferably it is 500-1000 mg / L as silicon, More preferably, it is 600-800 mg / L . In this case, the metasilicate concentrate can be diluted with water or the like at the time of use, and can be used as, for example, a 2% by volume solution or a 5% by volume solution.

  The metasilicate solution of the present invention is alkaline having a pH of 8 to 12, and usually exists as a colloidal solution. As a result of scanning electron microscope (SEM) measurement of this colloidal solution, fibrous colloidal particles are aggregated to form a porous spherical colloid (FIG. 1.1). On the other hand, the metasilicate solution described in Korean Patent No. 10-058952 is different in that the colloid solution is a slime mold colloid (FIG. 1.2). This indicates that the formation of colloidal particles varies greatly depending on the difference in the dissolution method of the water-soluble metasilicate.

  The metasilicate solution of the present invention can solve the problem of stability such as precipitation of metasilicate and the problem of stomach sag when ingested by a human by making the solution alkaline. . Furthermore, surprisingly, the present inventors have seen improvement of human renal function or diabetes pathology in alkaline metasilicate solution, whereas metasilicate solution described in Korean Patent No. 10-058952. Has obtained the knowledge that such an effect is not observed.

  When the metasilicate solution of the present invention is used as it is as a food or drink (for example, mineral water) or as a preventive or ameliorating agent for renal dysfunction or diabetes, the pH of the metasilicate solution is preferably 8-9. Moreover, when using as a concentrate which dilutes the metasilicate solution of this invention at the time of use, pH of a metasilicate solution becomes like this. Preferably it is 10-12. Higher pH improves the stability of the metasilicate solution.

The metasilicate solution may contain a pH adjusting agent in order to adjust the pH to an appropriate range. Examples of the pH adjuster include at least one selected from the group consisting of Na ⁺ , K ⁺ , Mg ²⁺ , Ca ²⁺ , Cl ⁻ , SO ₄ ²⁻ , HCO ₃ ⁻ , HPO ₄ ²⁻ and PO ₄ ^3−. Species ions can be used.

  The metasilicate solution of the present invention may contain other components other than the above components as long as the object of the present invention is not impaired.

The metasilicate solution of the present invention is preferably obtained by adding a metasilicate derived from a silicon oxide mineral, calcium or a calcium salt, and magnesium to water and performing a treatment such as boiling and cooling. Particularly preferably, metasilicate [Silypoly; sodium metasilicate decahydrate (Na ₂ SiO ₃ · 10H ₂ O)] is dissolved in radium hot spring water, and similarly dissolved aragonite-derived calcium and magnesium (for example, metallic magnesium) and It is obtained by mixing, boiling and cooling.

  The mixing ratio of metasilicate, calcium and magnesium can be adjusted as appropriate depending on the pH of the solution to be prepared, but preferably the weight ratio of metasilicate (as silicon): calcium: magnesium is about 1: 0. 00001-0.0005: 0.001-0.010.

  The metasilicate solution of the present invention may be used as it is in foods and drinks, oral preparations and the like, but is more preferably used as a concentrated solution in consideration of stability and the like. When used as a concentrate, for example, a metasilicate solution can be housed in a dropping bottle or the like, and a predetermined amount of the solution can be dripped into food and drink. Moreover, you may ingest the concentrate at a predetermined concentration with water or the like during use.

  The daily intake of the metasilicate solution of the present invention is in the range of about 1-50 mg, preferably about 1-20 mg, more preferably about 5-10 mg as silicon.

  When the metasilicate solution of the present invention is used for food and drink, the food and drink is not particularly limited, and can be used for general food and drink (for example, mineral water, cooked rice water, coffee, shochu split water, etc.). . From the effect of the metasilicate solution of the present invention on renal function or diabetes, it can also be used, for example, as a so-called health food or functional food.

  When the metasilicate solution of the present invention is used as a prophylactic or ameliorating agent for renal dysfunction or as a prophylactic or ameliorating agent for diabetes, its form is generally in the form of an aqueous solution, oily solution, suspension, emulsion, syrup or elixir. is there. These oral solutions may contain commonly used additives such as suspending agents, emulsifying agents, non-aqueous agents, preservatives, coloring agents, and fragrances. Examples of additives include almond oil, ethyl alcohol, coconut oil fraction, gelatin, glucose syrup, glycerin, hydrogenated edible oil, lecithin, methylcellulose, methyl or propyl para-hydroxybenzoate, propylene glycol, sorbitol, sorbic acid, etc. Is mentioned.

  The metasilicate solution of the present invention is not limited to a liquid agent, and may be added to tablets and capsules. Tablets and capsules include, in addition to metasilicate solutions, binders (eg, acacia gum, gelatin, polyvinylpyrrolidone, sorbitol, or tragacanth gum), bulking agents (eg, calcium phosphate, glycine, lactose, corn starch, sorbitol, sucrose) Etc.), a lubricant (eg, magnesium stearate, polyethylene glycol, silica, talc, etc.), a disintegrant (eg, potato starch), a fragrance, a colorant, a wetting agent and the like.

  EXAMPLES Hereinafter, although an Example demonstrates this invention further in detail, this invention is not limited to these Examples.

Example 1
(1) Preparation of water-soluble metasilicate 40.7 mg / L of water-soluble metasilicate as silicon, and pH adjuster [Aragonite-derived calcium (Arago Marine; manufactured by Gaiyatec Co., Ltd.) and magnesium (metallic magnesium; Nippon Heavy Industries, Ltd.) Kogyo Kogyo Co., Ltd.) was added to radium hot spring water and the pH was adjusted to 11 to prepare mineral concentrated water containing water-soluble metasilicate (hereinafter simply referred to as “mineral concentrated water”). As the water-soluble metasilicate, Siripoli (manufactured by Korea Escam) was used. The composition of the water-soluble metasilicate solution is shown in Table 1.

In this experiment, the prepared mineral concentrate was mixed with tap water at a ratio of 2% (v / v) and 5% (v / v) as a test substance.

(2) Evaluation animal:
In the test, 15 males of a group with abnormal glucose metabolism (KK / Ta jcl) were used per group, for a total of 45 males. KK / Ta mice are type II diabetes model mice exhibiting fasting hyperglycemia, impaired glucose tolerance, hyperinsulinemia, obesity, hyperlipidemia, and the like. In recent years, analysis using a gene chip confirmed strong expression of M-cadherin in liver and skeletal muscle. Furthermore, this M-cadherin gene polymorphism (SNP) and serum triglycerides, serum insulin, glucose tolerance, It has been reported that there is a significant correlation with body weight, and the usefulness as a model of type II diabetes and metabolic syndrome has been recognized again.
All animals were purchased from Nippon Claire Co., Ltd. at 4 weeks of age, and after quarantine / acclimation period, they were used for experiments from 5 weeks of age.

Experimental conditions:
Mouse breeding management and experiments were performed in a clean rack in the breeding room of the Animal Experiment Facility, Kagoshima University Frontier Science Research Promotion Center. The indoor environment at that time is set to a temperature of 22 ± 1 ° C., a humidity of 55 ± 10%, a ventilation rate of 12 times, and a lighting time of 12 hours, a normal feed (CE-2, manufactured by CLEA Japan, Inc.) and a high fat feed (HFD32, manufactured by Nippon Claire Co., Ltd.), tap water (control group) or mineral concentrated water (test group) was freely consumed.

Evaluation design KK / Ta mice are divided into 3 groups as shown in Table 2, and each group is bred with normal feed until 25 weeks of age, and thereafter with high fat feed, during which tap water (control group) or mineral concentrated water (2% intake group, 5% intake group) were given and the experiment was conducted.

General status and life / death, body weight, changes in food intake and water consumption:
All animals were visually observed once a week for general condition and life and death, and body weight, food intake and water consumption were measured using an electronic balance (AND GF-3000).
Organ weight ratio:
At 32 weeks of age, all mice were euthanized by exsanguination under pentobarbital anesthesia and the weight of each organ (heart, liver, kidney, spleen, pancreas, epididymal adipose tissue) was measured.

Blood biochemistry:
Twenty weeks after the start of the test (at 30 weeks of age), 10 animals were randomly selected from each group and subjected to blood biochemistry. Blood was collected from the target mice, and the samples were transported and examined at SRL.
The examination was performed on three items of neutral fat amount, total cholesterol amount and HDL cholesterol amount. These measurement items were performed at the time of eating. As for blood glucose level, blood was collected from the tail vein or orbital vein at the age of 32 weeks, and measured using a simple blood glucose measurement system Accu Check Compact (manufactured by Roche Diagnostics).
Urine sugar measurement:
Urine sugar was measured for all animals at 30 weeks of age at the time of feeding using Hitesper G (Eiken Chemical Co., Ltd.).

Statistical processing:
Each variable is shown as an average value ± standard deviation, and the statistical processing shown below was performed after the normality test using Statcel 2 (manufactured by OMS Publishing Co., Ltd.).
Regarding the weight change (g) of each group, the inter-individual variation, the experimental individual variation, the intra-individual variation, the interaction variation, and the error variation were analyzed by the duplicate measurement-ANOVA method. As for organ weight ratio (%), after normality and Barrett's test, mineral dispersion was administered by One-factor ANOVA when dispersion was considered uniform, and by Kruskal-Wallis test when dispersion was non-uniform. The effect was tested. If these tests confirm the effect of mineral concentrate, is there a significant difference between the control group and the 2% intake group or the 5% intake group using the Scheffe's F test? It was analyzed whether or not.

For food intake blood glucose level (mg / dL) and urine sugar (-), after normality and Barrett's test, Kruskal-Wallis test was used to test the effect of mineral concentrate administration. A Scheffe's F test was used.
For other blood biochemical variables, triglyceride (mg / dL) and total cholesterol (mg / dL) and HDL cholesterol (mg / dL), after normality test, mineral concentration by One-factor ANOVA The effect of water administration was tested.

result:
1. Changes in general condition and life / death, body weight, food intake / water intake in each group are shown in FIG. 2.1, and changes in food intake for each cage during the breeding period are shown in FIG. The water intake is shown in Figure 2.3.

As a result of statistical processing based on all measured values, the p-value is larger than 0.05 for both experimental individual variation and intra-individual variation, so it can be said that there is no difference in body weight due to the dose and duration of mineral concentrated water. .

  As findings at the time of necropsy, whitening of the liver was confirmed in each group (arrow head in Fig. 1.4), and it was confirmed that visceral fat was accumulated. Similarly, fat is highly accumulated around the epididymis (arrows in the figure), and it is presumed that visceral fat type metabolic syndrome can be induced. From the autopsy findings, it can be said that there is at least no acute toxicity in the concentration range of 2 to 5% (v / v).

2. Organ Weight Ratio The organ weight ratio (%) of each organ was determined by organ weight (g) / body weight (g) × 100. Moreover, the comparison for each organ is shown below (FIGS. 3.1 to 3.6).

2.1. Heart The organ weight ratio of the heart is shown in Figure 3.1. The numerical value of each group is 0.36 ± 0.04% (n = 16) in the control group, 0.36 ± 0.02% (n = 15) in the 2% intake group, and 0.36 in the 5% intake group. ± 0.02% (n = 14). As a result of statistical analysis, no change in the heart-organ weight ratio due to administration of mineral concentrate was confirmed (p> 0.05).

2.2. Liver Similarly, the liver / organ weight ratio (Fig. 3.2) was 5.20 ± 1.06% (n = 16) in the control group and 5.34 ± 1.09% (n = 15) in the 2% intake group. ) 5.35 ± 1.36% (n = 14) in the 5% intake group.

2.3. Kidney Kidney / organ weight ratios (Fig. 3.3, left kidney: a, right kidney: b) were 0.51 ± 0.04% left kidney and 0.52 ± 0.05% right kidney in the control group (n = 16) 0.51 ± 0.06% left kidney in the 2% intake group, 0.52 ± 0.06% right kidney (n = 15), 0.55 ± 0.06 left kidney in the 5% intake group %, Right kidney 0.55 ± 0.06% (n = 14). As a result of statistical analysis, the influence of mineral concentrated water intake was not observed (p> 0.05).

2.4. Pancreas For pancreas / organ weight ratio (Figure 3.4), control group 0.46 ± 0.09% (n = 16), 2% intake group 0.45 ± 0.07% (n = 15), 5 % Intake group was 0.39 ± 0.06% (n = 14), and as a result of statistical analysis, a change in the organ weight ratio due to the intake of mineral concentrated water was observed (p <0.05).
However, in the significant difference test by Scheffe's F test, there was no significant difference between the control group and the 2% intake group, between the control group and the 5% intake group, and between the 2% intake group and the 5% intake group.

2.5. Spleen The spleen / organ weight ratio was 0.35 ± 0.12% (n = 16) in the control group, 0.35 ± 0.07% (n = 15) in the 2% intake group, 0.32 ± in the 5% intake group At 0.07% (n = 14), the influence of mineral water intake was not confirmed (p> 0.05).

2.6. Epididymal adipose tissue High-fat diet ingests highly visceral fat around the epididymis of KK / Ta male mice, accounting for 2.73 ± 0.39% of body weight in the control group It has also increased to (n = 6). The effect of mineral concentrated water on this visceral fat is 3.29 ± 0.50% (n = 5) in the 2% intake group and 3.57 ± 0.68% (n = 4) in the 5% intake group, As a result of statistical analysis, no influence could be confirmed (p> 0.05).

3. Blood Biochemistry Test Next, the influence of mineral concentrate containing metasilicate on blood biochemical data was examined. Each indicator is described below.
3.1. Blood glucose level at the time of feeding The blood glucose level at the time of feeding (FIG. 4.1) of each group was 139.4 ± 44.39 mg / dL (n = 10) and 227.4 ± 76.90 in the control group.
mg / dL (n = 10) and 119.5 ± 31.32 mg / dL (n = 10).
As a result of statistical analysis, there was a significant difference between the control group and the 2% intake group, and between the 2% intake group and the 5% intake group (p <0.01).

3.2. Neutral fat mass The neutral fat mass (Fig. 4.2) in each group was 273.7 ± 143.43 mg / dL (n = 10) in the control group and 307.1 ± 188.56 mg / min in the 2% intake group. dL (n = 10), 299.1 ± 191.92 mg / dL (n = 10), and there was no significant difference between each group (p> 0.05).

3.3. Total cholesterol level The total cholesterol level (Fig. 4.3) was 182.7 ± 26.71 mg / dL (n = 10) in the control group and 163.0 ± 23.65 mg / dL (n = 10% in the 2% intake group). 10) It was 185.1 ± 24.63 mg / dL (n = 10) in the 5% intake group. As a result of statistical analysis, the effect of mineral concentrated water on the total cholesterol level in blood was not confirmed (p> 0.05).

3.4. HDL cholesterol level The blood HDL cholesterol level (FIG. 4.4) in each group was 100.33 ± 13.54 mg / dL (n = 9) in the control group and 92.9 ± 12.33 mg in the 2% intake group. / DL (n = 10) and 101.2 ± 11.74 mg / dL (n = 10) in the 5% ingestion group, and as a result of statistical analysis, there was no effect on the amount of HDL cholesterol in the concentrated mineral water ( p> 0.05).

4). Urine sugar measurement Urine sugar (-) was scored with 0 as 0, 1 as +, 2 as ++, and 3 as ++, and the measurement data at 30 weeks of age was used for statistical analysis. As a result, 2.3 ± 0.82 (n = 10) in the control group, 1.0 ± 1.05 (n = 10) in the 2% intake group, and 0.9 ± 1.20 in the 5% intake group ( n = 10). The difference between each group by multiple comparison test was detected as a significant difference between the control group and the 2% intake group (p <0.05) and between the control group and the 5% intake group (p <0.05). However, there was no significant difference between the 2% intake group and the 5% intake group (p> 0.05).

  Looking at the result of urine sugar measurement (FIG. 5.1), the detection of urine sugar is significantly reduced by the administration of mineral concentrated water. This suggests that mineral concentrate containing metasilicate may improve sugar reabsorption in the kidney.

It is a scanning electron microscope (SEM) photograph of the metasilicate solution of the present invention. 1 is a scanning electron microscope (SEM) photograph of a prior art metasilicate solution. It is a graph which shows the weight change during the test in each group. It is a graph which shows the change of the amount of food intake for every breeding gauge during the breeding period. It is a graph which shows the change of the water intake for every breeding gauge during breeding period. It is an autopsy photograph of each group (a. Control group, b. 2% intake group, c. 5% intake group). It is a graph which shows the heart / organ weight ratio (%) of each group. It is a graph which shows liver / organ weight ratio (%) of each group. It is a graph which shows the kidney / organ weight ratio (%) of each group. It is a graph which shows pancreas / organ weight ratio (%) of each group. It is a graph which shows spleen / organ weight ratio (%) of each group. It is a graph which shows the epididymal fat tissue / organ weight ratio (%) of each group. It is a graph which shows the blood glucose level (mg / dL) of each group. It is a graph which shows the amount of triglycerides (mg / dL) of each group. It is a graph which shows the total cholesterol amount (mg / dL) of each group. It is a graph which shows the amount of HDL cholesterol (mg / dL) of each group. It is a graph which shows the measurement result of urine sugar of each group.

Claims (10)

A metasilicate solution containing a water-soluble metasilicate and water and having a pH of 8 to 12, wherein the metasilicate obtained by baking and gasifying the silicon oxide mineral is recovered in water. dissolved, mixed with calcium and magnesium, boiling, by forming a being that porous spherical colloid obtained by cooling, the metasilicate solution.   The metasilicate solution according to claim 1, which is obtained from a complex aqueous solution containing a silicon silicate-derived metasilicate, calcium or calcium salt, and magnesium.   The metasilicate solution according to claim 1 or 2, comprising 10 to 1000 mg / L of metasilicate as silicon. The metasilicate solution according to claim 1 or 2, which contains 500 to 1000 mg / L of metasilicate as silicon. The metasilicate solution according to claim 1 or 2, comprising 10 to 100 mg / L of metasilicate as silicon. The metasilicate solution according to claim 4, wherein the pH is 10-12. The metasilicate solution according to claim 5, wherein the pH is 8-9. Food / beverage containing the metasilicate solution in any one of Claims 1-7.   The food and drink according to claim 8, which is mineral water.   A prophylactic or ameliorating agent for diabetes, comprising the metasilicate solution according to claim 1.